Heart Clinical Trials

Enroll in a Heart and Vascular Research Study

At the CentraCare Heart & Vascular Center, we know people take part in clinical research studies for many reasons. Some people want to help others who have cardiovascular problems or play a role in the discovery of new therapies. Others are looking to access groundbreaking treatments, new medications or the latest advancements in medical devices.

Whatever your motivation, you can find a variety of ongoing studies at the CentraCare Heart & Vascular Center. As one of Minnesota's largest heart hospitals, we are one of the few sites in the state with a department dedicated to heart research. Our goal is to find better ways to prevent, diagnose and treat heart disease so you can live better and longer.

Are Research Studies Safe?

The CentraCare Heart & Vascular Center Research Department undergoes rigorous review from the CentraCare – St. Cloud Hospital Institutional Review Board (IRB). The purpose of the IRB is to protect the rights and safety of people who volunteer to take part in research studies. To contact the IRB, call 320-251-2700, ext. 55716.

Current Studies

CentraCare offers a variety of cardiovascular research studies focused on prevention, heart failure and devices. Learn more about enrolling in research studies.

Heart Clinical Trials team member

Contact Us

For more information about our heart research studies, call 320-251-2700, ext. 57584, or e-mail CCHVC-Research@centracare.com.

If you would like to support clinical research at CentraCare, please make a gift to CentraCare Foundation.

Make a gift

Prevention Studies

AZD0780 - D7960C00015: This phase III study assesses the effect of AZD0780 compared with placebo in reducing the risk of major adverse cardiovascular events (MACE-PLUS) in participants with established atherosclerotic cardiovascular disease (ASCVD) or those at high risk for a first ASCVD event.

More information

DAL-GENE-2: This study evaluates the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal heart attacks in patients with a documented recent acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene.

More information

ZENITH: This study evaluates whether zilebesiran versus placebo reduces the risk of major cardiovascular events in adult patients with either established cardiovascular disease or a high risk for cardiovascular disease who have hypertension that is not adequately controlled.

More information

Heart Failure Studies

CORCINCH-HF: This clinical study evaluates the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).

More information

EMPOWER: This clinical trial assesses the safety and efficacy of the Carillon Mitral Contour System in treating heart failure patients who have early-stage functional mitral regurgitation (FMR).

More information

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III: This study evaluates the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III heart failure patients (PROACTIVE-HF-2 Trial).

More information

SYNCHRONICITY: This study compares two different methods to pace the heart to treat heart failure including:

The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called cardiac resynchronization therapy (CRT).
The other method is using a lead implanted in the left bundle branch area (LBBA) of your heart. This method is called left bundle branch area pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.

More information

Device Studies

AUTO-BLOOD PE (Autologous Transfusion Observation of Blood Quality in PE): This study characterizes the peri-procedural changes in blood biomarkers of hemolysis, coagulation/thrombosis, organ function and systemic inflammation in patients undergoing commercial thrombectomy for acute pulmonary embolism.

COMPLETE TAVR: Among patients who have undergone a successful elective transfemoral TAVR, this study will determine whether a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new heart attack, ischemia driven revascularization or hospitalization.

More information

CONFORM: This study evaluates if the CLAAS® device is similar in safety and efficacy to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation.

More information

EPX-HTG-2025: This study reviews the safety and efficacy of EchoPixel Holographic Therapy Guidance (HTG) Procedural WATCHMAN FLX with TRUSTEER implantation.

PREVAIL GLOBAL: The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail drug-coated balloon.

More information

PROGRESS CAP: This study’s objective is to establish the safety and effectiveness of the Edwards SAPIEN 3/ SAPIEN 3 Ultra Transcatheter Heart Valve in subjects with moderate, calcific aortic stenosis.

More information

QUADRA-PE: This study examines the safety and effectiveness of the Akura Thrombectomy System for use in the removal of emboli from the pulmonary arteries in treating acute pulmonary embolism (PE).

More information

SUPPORT II: This trial looks at the safety and effectiveness of utilizing the Supira System to provide temporary ventricular support in patients undergoing high-risk percutaneous coronary intervention (HRPCI).

More information